AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C.
Georgiou E, Kagiava A, Sargiannidou I, Schiza N, Stavrou M, Richter J, Tryfonos C, Heslegrave A, Zetterberg H, Christodoulou C, Kleopa KA.
Georgiou E, et al. Among authors: stavrou m.
Mol Ther. 2023 Nov 1;31(11):3290-3307. doi: 10.1016/j.ymthe.2023.08.020. Epub 2023 Aug 28.
Mol Ther. 2023.
PMID: 37641403
Free article.